Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

Helus Pharma's APPROACH Phase 3 trial for HLP003, a potential new treatment for major depressive disorder, is on track and has exceeded 86% enrollment, indicating strong interest from participants. The trial builds on promising results from Phase 2, where HLP003 showed a significant 23-point reduction in depression symptoms over a year. This progress is crucial as it moves the potential new therapy closer to market, offering hope for more effective treatments for those struggling with MDD. The advancement of this trial could have significant implications for mental health treatment options.